arterial wall thickening atherosclerosis
Conditions
Interventions
Sponsors
Academisch Medisch Centrum
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: - Subjects with diagnosis of Familial dysbetalipoproteinemia (type III hyperlipoproteinemia) - Aged 50 years or older - No treatment with lipid lowering drugs or willing to stop lipid lowering therapy for 6 weeks prior to baseline measurements
Exclusion criteria
Exclusion criteria: 1 . Malignant diseases or any other clinically significant medical condition that could interfere with the conduct of the study in the opinion of the investigator 2 . Standard contra-indications to MRI and 18F-FDG PET/CT based on physicians experience and current practices: Claustrophobia, metal in the body, as a result of e.g. osteosynthetic material, pacemaker implantation of artificial cardiac valves. 3. Clinical signs of acute infection and/or CRP > 10 4 . Participation in a scientific study with radiation exposure in the year prior to inclusion or planned radiation exposure in the next year due to participation in a research project with radiation exposure or for clinical reasons 5. Recent (
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main study parameters are arterial wall inflammation (target-to-background ratio) measured by 18F-FDG PET/CT and vessel wall dimensions measured by MRI. | — |
Secondary
| Measure | Time frame |
|---|---|
| - Trans endothelial migration (TEM) of monocytes - Monocyte subtyping by FACS analysis using a CD14, CD16 and HLA-DR backbone. - In vitro cytokine production by using isolated monocytes of subjects. - Epigenetic changes in genes identified with FACS or in vitro stimulation assays. | — |
Countries
The Netherlands
Outcome results
None listed